Skip to main content
Log in

The measurement of urinary amino-terminal telopeptides of type I collagen to monitor bone resorption in patients with primary hyperparathyroidism

  • Comment
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

This study was carried out in order to evaluate clinical usefulness of cross-linked N-telopeptides (NTx) of type I collagen determination, in patients with primary hyperparathyroidism. Twenty-six consecutive patients (6 males and 20 females, aged 56.3±15.0, SD, yrs) with primary hyperparathyroidism were studied in basal conditions and, ten of them, after surgical cure of the disease. Cross-linked collagen peptides were measured by enzyme-linked immunosorbent assay and conventional markers of bone turnover according to standard procedures. Bone densitometry at the lumbar spine and proximal femur was performed using dual-energy X-ray absorptiometry. Bone mineral density was also assessed at the junction of the distal and middle third of the radius and at the ultradistal radius of the non-dominant arm by a dual photon densitometer. Mean urinary NTx values (194.2±121.9 pmoles bone collagen equivalents/pinoles creatinine) were significantly higher (p<0.001) in respect to those found in normal subjects. The mean increase of Z score values of both serum tartrate resistant acid phosphatase activity (1.4±1.8) and the fasting hydroxyproline/creatinine ratio (1.45±2.0) was significantly lower (p<0.02) in respect to that of NTx Z score values (3.3±3.3); the latter values were not significantly different than mean Z score values of serum osteocalcin (4.0±3.9), serum alkaline phosphatase activity (2.6±2.6) and urinary calcium/creatinine ratio (3.2±3.3). We found a significant inverse correlation between NTx values and both lumbar spine (p<0.01) and ultradistal radius bone mineral density (p<0.05); a modest inverse correlation was also observed between serum tartrate resistant acid phosphatase activity and lumbar spine bone mineral density (p<0.04). Following successful adenoma removal, the percentage decrease of both NTx and hydroxyproline was similar in patients with increased bone turnover rate; major discrepancies were observed in patients with normal values of NTx, the telopeptide reduction being greater than that of hydroxyproline. Finally, in a hypercalcemic patient with metastatic parathyroid cancer, telopeptide excretion was shown to be more sensitive in respect to urinary hydroxyproline when evaluating the effects of antiresorptive therapy. Our results seem to indicate that amongst the markers with good sensitivity, NTx is the only one that is inversely related with bone mineral density at two different skeletal sites. This assay should therefore have a place in both the initial screening and medical follow-up of patients with this glandular disorder; in fact, in both situations an increased urinary excretion of this marker should warn about the possibility of hidden bone loss.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Heath H. III. Clinical spectrum of primary hyperparathyroidism: evolution with changes in medical practice and technology. J. Bone Miner. Res. 6(Suppl. 2): S63, 1991.

    PubMed  Google Scholar 

  2. Minisola S., Rosso R., Romagnoli E., Pacitti M.T., Scarnecchia L., Carnevale V., Mazzuoli G.F. Trabecular bone mineral density in primary hyperparathyroidism: relationship to clinical presentation and biomarkers of skeletal turnover. Bone Miner. 20: 113, 1993.

    Article  CAS  PubMed  Google Scholar 

  3. Consensus Development Conference Panel. Diagnosis and management of asymptomatic primary hyperparathyroidism: consensus development conference statement. Ann. Intern. Med. 114: 593, 1991.

    Article  Google Scholar 

  4. Hanson D.A., Weis M.A.E., Bollen A.M., Maslan S.L., Singer F.R., Eyre D.R. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner. Res. 7: 1251, 1992.

    Article  CAS  PubMed  Google Scholar 

  5. Harris S.T., Gertz B.J., Eyre D.R., Genant H.K., Survill T.T., Chesnut C.H. The effect of short-term treatment with alendronate upon vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J. Clin. Endocrinol. Metab. 76: 1399, 1993.

    CAS  PubMed  Google Scholar 

  6. Gertz B.J., Shao P., Hanson D.A., Quan H., Harris S.T., Genant H.K., Chesnut III C.H., Eyre D.R. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner. Res. 9: 135, 1994.

    Article  CAS  PubMed  Google Scholar 

  7. Minisola S., Pacitti M.T., Scarda A., Rosso R., Romagnoli E., Carnevale V., Scarnecchia L., Mazzuoli G.F. Serum ionized calcium, parathyroid hormone and related variables: effects of age and sex. Bone Miner. 23: 183, 1993.

    Article  CAS  PubMed  Google Scholar 

  8. Minisola S., Romagnoli E., Scarnecchia L., Rosso R., Pacitti M.T., Scarda A., Mazzuoli G.F. Serum carboxy-terminal propeptide of human type I procollagen in patients with primary hyperparathyroidism: studies in basal conditions and after parathyroid surgery. Eur. J. Endocrinol. 130: 587, 1994.

    Article  CAS  PubMed  Google Scholar 

  9. Romagnoli E., Minisola S., Carnevale V., Scarda A., Rosso R., Scarnecchia L., Pacitti M.T., Mazzuoli G.F. Effect of estrogen deficiency on IGF-I plasma levels: relationship with bone mineral density in perimenopausal women. Calcif. Tissue Int. 53: 1, 1993.

    Article  CAS  PubMed  Google Scholar 

  10. Rowe J.W., Andres R., Tobin J.D., Norris A.H., Shock N.W. Age-adjusted standards for creatinine clearance. Ann. Intern. Med. 84: 567, 1976.

    Article  CAS  PubMed  Google Scholar 

  11. Papapoulos S.E., Frolich M., Mudde A.H., Harinck H.I.J., Berg H.V.D., Bijvoet O.L.M. Basal concentrations and response to bisphosphonate treatment. J. Clin. Endocrinol. Metab. 65: 89, 1987.

    Article  CAS  PubMed  Google Scholar 

  12. Thiebaud D., Jaeger P., Gobelet C., Jaquet A.F. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget’s disease of bone. Am. J. Med. 85: 207, 1990.

    Article  Google Scholar 

  13. Minisola S., Carnevale V., Pacitti M.T., Romagnoli E., Scarnecchia L., Rosso R., Minisola G., Mazzuoli G.F. Serum osteocalcin in metabolic bone disease: what is its real significance? J. Endocrinol. Invest. 16: 277, 1993.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Minisola, S., Pacitti, M.T., Rosso, R. et al. The measurement of urinary amino-terminal telopeptides of type I collagen to monitor bone resorption in patients with primary hyperparathyroidism. J Endocrinol Invest 20, 559–565 (1997). https://doi.org/10.1007/BF03348019

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03348019

Key-words

Navigation